CORRECTION

Open Access

Check for updates

Correction: Masitinib for mild-to-moderate Alzheimer's disease: results from a randomized, placebo-controlled, phase 3, clinical trial

Bruno Dubois^{1*}, Jesús López-Arrieta², Stanley Lipschitz³, Triantafyllos Doskas⁴, Luiza Spiru^{5,6}, Svitlana Moroz⁷, Olena Venger⁸, Patrick Vermersch⁹, Alain Moussy¹⁰, Colin D. Mansfield¹⁰, Olivier Hermine^{10,11,12*}, Magda Tsolaki¹³ and for the AB09004 Study Group Investigators

Correction: Alz Res Therapy 15, 39 (2023) https://doi.org/10.1186/s13195-023-01169-x

Following publication of the original article [1], the authors identified an error in the author name of Triantafyllos Doskas. The given name and family name were reversed.

The incorrect author name is: Doskas Triantafyllos

The correct author name is: Triantafyllos Doskas

The author group has been updated above and the original article [1] has been corrected.

Reference

1. Dubois B, López-Arrieta J, Lipschitz S, et al. Masitinib for mild-to-moderate Alzheimer's disease: results from a randomized, placebo-controlled, phase 3, clinical trial. Alz Res Therapy. 2023;15:39. https://doi.org/10.1186/ s13195-023-01169-x.

Published online: 22 April 2023

The original article can be found online at https://doi.org/10.1186/s13195-023-01169-x.

*Correspondence:

Bruno Dubois

- bruno.dubois@aphp.fr
- Olivier Hermine
- ohermine@gmail.com
- ¹ Alzheimer Research Center IM2A, Salpêtrière Hospital, AP-HP, Sorbonne University, Paris, France
- ² Cantoblanco Memory Clinic, Geriatric Department, Hospital
- Cantoblanco, Madrid, Spain

 3 The Dr Stanley Lipschitz Clinic Inc, Rosebank, Johannesburg, South Africa

⁴ Neurological Department, Athens Naval Hospital, Athens, Greece ⁵ Carol Davila University of Medicine and Pharmacy, The Excellence Clinic of Geriatrics, Gerontology and Old Age Psychiatry, Bucharest, Romania ⁶ The Excellence Memory Center and Longevity Medicine, "Ana Aslan" International Foundation, Bucharest, Romania

⁷ Psychosomatic Center Based On Psychoneurology Department of Communal Enterprise 'Dnipropetrovsk Regional Clinical Hospital Named After 1.I. Mechnikov', Dnipropetrovsk Regional Council, Dnipro, Ukraine ⁸ Department Psychiatry, Narcology and Medical Psychology I, Horbachevsky Ternopil National Medical University, Ternopil, Ukraine ⁹ Univ. Lille, UMR Inserm U1172, CHU Lille, FHU Precise, F-59000 Lille, France ¹⁰ AB Science, Paris, France

¹² Department of Hematology, Necker Hospital, Assistance Publique Hôpitaux de Paris, Paris, France

¹³ First Department of Neurology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Macedonia, Greece



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

¹¹ Imagine Institute, INSERM UMR 1163, University of Paris, Laboratory of Cellular and Molecular Mechanisms of Hematological Disorders and Therapeutic Implication, Hôpital Necker, Paris, France